利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.018 秒)

    Methods and compositions concerning siRNA's as mediators of RNA interference
    1.
    发明授权
    Methods and compositions concerning siRNA's as mediators of RNA interference 有权
    关于siRNA作为RNA干扰介体的方法和组成

    公开(公告)号：US08058255B2

    公开(公告)日：2011-11-15

    申请号：US12484948

    申请日：2009-06-15

    申请人： Lance P. Ford ,  Joseph Krebs

    发明人： Lance P. Ford ,  Joseph Krebs

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： C12N15/111 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2330/30 ,  C12Y102/01012 ,  C12Y502/01008

    摘要： The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.

    摘要翻译： 本发明涉及介导RNA干扰的约5至约20个核苷酸的分离的siRNA。 还公开了减少细胞中靶基因表达的方法，包括获得至少一种5,6,7,8,9,10,11,12,13,14,15,16,17,18,19种的siRNA ，或20个碱基对长度; 并将siRNA递送到细胞中。 siRNA可以是化学合成的RNA或天然存在的RNA的类似物。

    METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE
    2.
    发明申请
    METHODS AND COMPOSITIONS CONCERNING siRNA'S AS MEDIATORS OF RNA INTERFERENCE 有权
    关于siRNA作为RNA干扰介质的方法和组合物

    公开(公告)号：US20100159591A1

    公开(公告)日：2010-06-24

    申请号：US12484948

    申请日：2009-06-15

    申请人： Lance P. Ford ,  Joseph Krebs

    发明人： Lance P. Ford ,  Joseph Krebs

    IPC分类号： C12N5/00 ,  C07H21/02

    CPC分类号： C12N15/111 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2330/30 ,  C12Y102/01012 ,  C12Y502/01008

    摘要： The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.

    摘要翻译： 本发明涉及介导RNA干扰的约5至约20个核苷酸的分离的siRNA。 还公开了减少细胞中靶基因表达的方法，包括获得至少一种5,6,7,8,9,10,11,12,13,14,15,16,17,18,19种的siRNA ，或20个碱基对长度; 并将siRNA递送到细胞中。 siRNA可以是化学合成的RNA或天然存在的RNA的类似物。

    Optimized pricing solver with prioritized constraints
    3.
    发明授权
    Optimized pricing solver with prioritized constraints 有权
    优化定价解决器优先约束

    公开(公告)号：US08311878B2

    公开(公告)日：2012-11-13

    申请号：US13113492

    申请日：2011-05-23

    申请人： Shivaram Subramanian ,  Aihua Xu ,  Joseph Krebs

    发明人： Shivaram Subramanian ,  Aihua Xu ,  Joseph Krebs

    IPC分类号： G06Q10/00 ,  G06Q30/00

    CPC分类号： G06Q10/04

    摘要： A pricing optimization system can solve a constrained optimization problem by generating one or more prices for one or more items that satisfy a maximum number of prioritized constraints. The one or more generated prices can be one or more prices that represent a minimal deviation between the generated one or more prices and one or more original prices for the one or more items. By satisfying a maximum number of prioritized constraints, and by minimizing a deviation from the one or more original prices for the one or more items, the generated one or more prices are one or more optimal prices.

    摘要翻译： 定价优化系统可以通过为满足最大数量的优先约束的一个或多个项目生成一个或多个价格来解决约束优化问题。 一个或多个生成的价格可以是一个或多个价格，其代表所生成的一个或多个价格与一个或多个物品的一个或多个原始价格之间的最小偏差。 通过满足优先约束的最大数量，并且通过最小化与一个或多个项目的一个或多个原始价格的偏差，所生成的一个或多个价格是一个或多个最优价格。

    Methods and compositions concerning siRNA's as mediators of RNA interference
    4.
    发明申请
    Methods and compositions concerning siRNA's as mediators of RNA interference 审中-公开
    关于siRNA作为RNA干扰介体的方法和组成

    公开(公告)号：US20060142228A1

    公开(公告)日：2006-06-29

    申请号：US11020560

    申请日：2004-12-23

    申请人： Lance Ford ,  Joseph Krebs

    发明人： Lance Ford ,  Joseph Krebs

    IPC分类号： A61K48/00 ,  C12Q1/68 ,  C07H21/02

    CPC分类号： C12N15/111 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2330/30 ,  C12Y102/01012 ,  C12Y502/01008

    摘要： The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.

    摘要翻译： 本发明涉及介导RNA干扰的约5至约20个核苷酸的分离的siRNA。 还公开了减少细胞中靶基因表达的方法，包括获得至少一种5,6,7,8,9,10,11,12,13,14,15,16,17,18,19种的siRNA ，或20个碱基对长度; 并将siRNA递送到细胞中。 siRNA可以是化学合成的RNA或天然存在的RNA的类似物。

    Low-cost production of peptides
    5.
    发明申请
    Low-cost production of peptides 有权
    低成本生产肽

    公开(公告)号：US20050227321A1

    公开(公告)日：2005-10-13

    申请号：US10971444

    申请日：2004-10-22

    申请人： Joseph Krebs ,  Paul Zorner ,  Ian Tomlinson

    发明人： Joseph Krebs ,  Paul Zorner ,  Ian Tomlinson

    IPC分类号： C07H21/04 ,  C07K5/06 ,  C07K14/47 ,  C12N1/21 ,  C12N9/48 ,  C12N15/74 ,  C12P21/04 ,  C12P21/06

    CPC分类号： C07K14/4723 ,  C07K2319/35 ,  C07K2319/50

    摘要： The subject invention relates to a low cost method of producing peptides, including antimicrobial peptides (AMPs), by using microbes. The subject methods enable greatly improved yields of the peptide/AMP as compared to those heretofore known in the art. The subject methods also surprisingly enable the use of Pseudomonas fluorescens to produce AMPs and other peptides. There are several components of the subject invention, which can be used alone or in combination. The subject invention provides for the production of peptides/AMPs in concatemeric precursors. The subject invention also provides novel methods of assembling monomers into multimers, and of cleaving the multimers to yield active monomers. The subject invention also relates to the use of these multimers fused to carrier peptides to produce fusion proteins. Preferably, both the multimers and the fusion proteins (multimers with the carrier polypeptides) lack charge balancing. It has been surprisingly determined that it is not necessary to offset the positive charges of multiple copies of AMPs in multimeric constructs. Thus, the subject invention enables the use of a wider range of multimers and carrier peptides.

    摘要翻译： 本发明涉及通过使用微生物生产肽（包括抗微生物肽（AMP））的低成本方法。 与本领域已知的方法相比，本发明方法能够大大提高肽/ AMP的产率。 本发明的方法也令人惊奇地使得能够使用荧光假单胞菌来产生AMP和其他肽。 本发明的几个组分可单独使用或组合使用。 本发明提供了在并联前体中生产肽/ AMP。 本发明还提供了将单体组装成多聚体的新方法，以及裂解多聚体以产生活性单体。 本发明还涉及这些与载体肽融合的多聚体产生融合蛋白的用途。 优选地，多聚体和融合蛋白（携带多肽的多聚体）都缺乏电荷平衡。 已经令人惊讶地确定，不需要在多聚体构建体中抵消多个拷贝的AMP的正电荷。 因此，本发明使得能够使用更宽范围的多聚体和载体肽。

    Production of anti-peptide antibodies
    6.
    发明授权
    Production of anti-peptide antibodies 有权

    公开(公告)号：US09745353B2

    公开(公告)日：2017-08-29

    申请号：US13990344

    申请日：2011-11-29

    申请人： Joseph Krebs ,  Paul Morrison ,  Jun Wang

    发明人： Joseph Krebs ,  Paul Morrison ,  Jun Wang

    IPC分类号： C07K14/195 ,  C07K16/00 ,  A61K39/00 ,  C07K19/00 ,  C07K16/40 ,  C12N9/02

    CPC分类号： C07K14/195 ,  A61K2039/6031 ,  A61K2039/6043 ,  C07K14/245 ,  C07K16/00 ,  C07K16/40 ,  C07K2319/00 ,  C12N9/0008 ,  C12N15/62

    摘要： Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates. These recombinant antigen-carriers are designed to specifically aggregate in vivo after administration into the host; this aggregation greatly enhances immunogenicity and may eliminate the need for the use of chemical adjuvants which cause physical irritation and discomfort to the host.

    IMPROVED PRODUCTION OF ANTI-PEPTIDE ANTIBODIES
    9.
    发明申请
    IMPROVED PRODUCTION OF ANTI-PEPTIDE ANTIBODIES 有权
    改进生产抗肽抗体

    公开(公告)号：US20140046035A1

    公开(公告)日：2014-02-13

    申请号：US13990344

    申请日：2011-11-29

    申请人： Joseph Krebs ,  Paul Morrison ,  Jun Wang

    发明人： Joseph Krebs ,  Paul Morrison ,  Jun Wang

    IPC分类号： C07K14/195 ,  C12N9/02

    CPC分类号： C07K14/195 ,  A61K2039/6031 ,  A61K2039/6043 ,  C07K14/245 ,  C07K16/00 ,  C07K16/40 ,  C07K2319/00 ,  C12N9/0008 ,  C12N15/62

    摘要： Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates. These recombinant antigen-carriers are designed to specifically aggregate in vivo after administration into the host; this aggregation greatly enhances immunogenicity and may eliminate the need for the use of chemical adjuvants which cause physical irritation and discomfort to the host.

    摘要翻译： 抗肽抗体（APAs）是生物医学研究的重要工具。 许多重要的技术，如免疫印迹，ELISA免疫测定，免疫细胞化学和蛋白质微阵列与APA功能本质上相关，完全依赖于APA质量。 不幸的是，并非所有商业上可获得的APA具有良好的抗原结合特征; 因此，研究人员往往无法进行高质量的蛋白质分析实验。 本公开描述了使用重组抗原可扩展生产多克隆APA的新方法。 这些重组肽抗原与传统的肽抗原相比具有几个优点，其提高抗体生产的容易性和速度。 重组抗原可以比传统的合成肽缀合物更快地产生和纯化。 这些重组抗原载体被设计为在给予宿主后在体内特异性聚集; 这种聚集大大增强免疫原性，并且可以消除使用引起身体对主体的刺激和不适的化学助剂的需要。